Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2011-02-23 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCTs encapsulating technology granted key Australian patent 2 pages 35.1KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited about the granting of an Australian patent for their encapsulating technology. It is a news release focused on intellectual property and product development progress, not a financial report, regulatory filing, or meeting material. There are no financial statements, management discussions, or voting results. The content is a corporate announcement about a patent grant, which fits best under general regulatory announcements or miscellaneous filings that do not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 5810 characters, which is sufficient for a full announcement rather than a brief notice or report publication announcement.
2011-02-23 English
International foundations team up to fund LCT NZ Trial 4 pages 314.3KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited about funding received from charitable foundations to support the completion of a Phase II clinical trial for their DIABECELL treatment for Type 1 diabetes. It discusses the trial progress, funding details, and background information about the company and the foundations. There are no financial statements, regulatory filings, or detailed financial results presented. The content is primarily an update on financing support for clinical trials, which relates to capital or financing activities rather than a full financial report or earnings release. The document length is over 11,000 characters, indicating it is not a brief announcement but a detailed update. Given the focus on funding and trial progress, the most appropriate classification is Capital/Financing Update (CAP).
2011-02-15 English
Appendix 3B 8 pages 132.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, issue price, purpose of the issue, and quotation details for the Australian Securities Exchange (ASX). It references ASX rules and includes a quotation agreement. The content is consistent with a formal announcement of new share issuance and application for quotation of additional securities, which aligns with announcements related to share issues or capital changes. The document is over 10,000 characters, indicating it is a full announcement rather than a brief notice. There is no indication that this is a full financial report, audit report, or management discussion. It is not a proxy statement, dividend notice, or earnings release. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA).
2011-02-01 English
Cleansing Statement 1 page 25.7KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. It is a formal announcement about a share issue related to a convertible security agreement. The document is short (1240 characters) and focuses on compliance and disclosure related to share issuance, not a full financial report or detailed analysis. This fits the category of Share Issue/Capital Change announcements rather than a full report or regulatory filing. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2011-02-01 English
Share Placement with ASK 3 pages 48.7KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited regarding a new equity investment by Jiangsu Aosaikang Pharmaceutical, detailing the terms of the share placement, the amount raised, and the intended use of proceeds. It discusses a strategic collaboration and investment but does not contain financial statements, quarterly or annual results, or detailed financial analysis. The document is focused on capital raising and partnership agreements, which aligns with updates on financing activities or capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not merely an announcement of a report or a regulatory filing. Confidence is high due to clear content focus on share placement and investment terms.
2011-01-30 English
Appendix 4C - quarterly 7 pages 115.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 December 2010' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It includes financial figures for the quarter ended 31 December 2010 and year-to-date, as well as notes on payments to directors and compliance statements. The document is a comprehensive quarterly financial report with substantive financial data and analysis, not merely an announcement or certification. The presence of detailed cash flow statements and financial data for a quarter indicates it is an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR'. Q4 2010
2011-01-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.